Enanta Pharmaceuticals公司的背景是什麼？

詳細公司背景可參考: [http://www.enanta.com](http://www.enanta.com)。

Enanta Pharmaceuticals

ENTA

39.270

▼3.100

▼7.32%

概況消息

最少15分鐘延遲，股票資訊由第三方資訊供應商提供

・Enanta Pharmaceuticals - 延遲價格・最後更新於 24/05 8:25

最高位: 41.610
最低位: 38.910
開市價: --
前收市價: 42.370
成交量(千): 13.17
成交額(百萬): 4.32
買入: --
賣出: --
每手股數: --
市值(百萬): 813.39
市盈率: --
息率: --
差價: --
52週高低: 102.000 - 38.020

所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱: Enanta Pharmaceuticals
證券代碼: ENTA.US
所屬板塊: Biotechnology
公司業務: Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
發行量: 20214850
公司總部: 500 Arsenal Street
公司網址: http://www.enanta.com
公司電郵: jviera@enanta.com
公司電話: +1 617 607-0800

關於

Enanta Pharmaceuticals(ENTA.US)所屬的行業板塊為Biotechnology。

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

詳細公司背景可參考: http://www.enanta.com。

快訊

資訊

虛擬市場

Enanta Pharmaceuticals

企業資料

最新發佈

關於